Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines for patients with cancer and inflammatory diseases. The company's website is www.nurix.com.

Nurix operates through a combination of wholly owned and partnered drug discovery pipelines. The company's wholly owned clinical pipeline includes three investigational drug candidates: bexobrutideg, a highly selective degrader of Bruton's tyrosine kinase for relapsed or refractory B-cell malignancies; zelebrudomide, a dual degrader of BTK and transcription factors IKZF1 and IKZF3; and NX-1607, an inhibitor of CBL-B for solid tumor indications. The company is also advancing multiple preclinical-stage targeted protein degraders and degrader antibody conjugates across oncology, inflammation and immunology indications.

Nurix's partnered pipeline includes collaborations with Gilead Sciences, Sanofi and Pfizer. Through these partnerships, the company has received $482 million in non-dilutive financing as of November 2025 and is eligible to receive up to $6.1 billion in potential future fees and milestone payments plus royalties on product sales. The company retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates.

The company's core competitive advantage is its DEL-AI discovery engine, an artificial intelligence-integrated platform that employs advanced machine learning to identify novel chemical starting points for drug discovery. The platform leverages hundreds of billions of DNA-encoded library compound binding signatures and automated chemistry synthesis capabilities to rapidly generate degraders and degrader antibody conjugates as new chemical entities. This technology enables the company to identify binders for targets previously considered undruggable.

Nurix has never generated revenue from product sales and has incurred significant losses since inception. The company expects to require substantial additional funding to advance its clinical programs and support future commercialization efforts. As of January 23, 2026, the company had shares of common stock outstanding and is classified as an accelerated filer with the Securities and Exchange Commission.